LCTX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

LCTXLineage Cell Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

LCTXLineage Cell Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LCTX 12

—Cell Cure Neurosciences Ltd. (CCN)unlistedsupplier

—Hadasitunlistedsupplier

—Cancer Research Technology (CRT)unlistedsupplier

—Israel Innovation Authority (IIA)unlistedsupplier

8 more · LCTX chain ›

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

LCTXLineage Cell Therapeutics, Inc.

0.99· pre 0.98· delayed

Mkt cap$248.6MRevenue$1MQ2 FY26Revenue$15MFY25

AMGNAmgen Inc

461.49· pre 448.30· delayed

Pre-marketNov 6 '26delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 6 '26delayed

LCTXLineage Cell Therapeutics, Inc.

AMGNAmgen Inc

0.99pre 0.98delayed

Price

461.49pre 448.30delayed

$248.6M

Mkt cap

$249.0B

Q2 FY26$1M

Revenue

$10.4BQ3 FY26

FY25$15M

Revenue

$36.8BFY25

LCTX0.99vsAMGN461.49Pre-marketNov 6 '26delayed